Points clés de l’étude

Points clés de l’étude1,2

DOR/3TC/TDF=100 mg de doravirine, 300 mg de lamivudine et 300 mg de fumarate de ténofovir disoproxil;
EFV/FTC/TDF=600 mg d’éfavirenz, 200 mg d’emtricitabine et 300 mg de fumarate de ténofovir disoproxil

Bibliographie:

  1. Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68(4):535-544.
  2. Supplement to: Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis.
    2019;68(4):535-544.

DZ-DOR-00009. Date d’expiration: 1-10-2026